Andreas Krämer

Andreas Krämer

Auto-generated profile, based on publicly available information

Andreas Krämer

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt am Main, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
MWMarek Wanior
Marek Wanior
AKAndreas Krämer
Andreas Krämer
SKStefan Knapp
Stefan Knapp
AJAndreas C Joerger
Andreas C Joerger
Multi-subunit ATPase-dependent chromatin remodelling complexes SWI/SNF (switch/sucrose non-fermentable) are fundamental epigenetic regulators of gene transcription. Functional genomic studies revealed a remarkable mutation prevalence of SWI/SNF-encoding genes in 20–25% of all human cancers, frequently driving oncogenic programmes. Some SWI/SNF-mutant cancers are hypersensitive to perturbations in other SWI/SNF subunits, regulatory proteins and distinct biological pathways, often resulting in sustained anticancer effects and synthetic lethal interactions. Exploiting these vulnerabilities is a promising therapeutic strategy. Here, we review the importance of SWI/SNF chromatin remodellers in gene regulation as well as mechanisms leading to assembly defects and their role in cancer development. We will focus in particular on emerging strategies for the targeted therapy of SWI/SNF-deficient cancers using chemical probes, including proteolysis targeting chimeras, to induce synthetic lethality.

23 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
QWQin Wu
Qin Wu
DHDavid Heidenreich
David Heidenreich
SZStanley Zhou
Stanley Zhou
SASuzanne Ackloo
Suzanne Ackloo
AKAndreas Krämer
Andreas Krämer
SKStefan Knapp
Stefan Knapp
Bromodomains (BRDs) are conserved protein interaction modules which recognize (read) acetyl-lysine modifications, however their role(s) in regulating cellular states and their potential as targets for the development of targeted treatment strategies is poorly understood. Here we present a set of 25 chemical probes, selective small molecule inhibitors, covering 29 human bromodomain targets. We comprehensively evaluate the selectivity of this probe-set using BROMOscanand demonstrate the utility of the set identifying roles of BRDs in cellular processes and potential translational applications. For instance, we discovered crosstalk between histone acetylation and the glycolytic pathway resulting in a vulnerability of breast cancer cell lines under conditions of glucose deprivation or GLUT1 inhibition to inhibition of BRPF2/3 BRDs. This chemical probe-set will serve as a resource for future applications in the discovery of new physiological roles of bromodomain proteins in normal and disease states, and as a toolset for bromodomain target validation.

28 February 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
NBNadilly Bonagas
Nadilly Bonagas
NGNina M. S. Gustafsson
Nina M. S. Gustafsson
MHMartin Henriksson
Martin Henriksson
PMPetra Marttila
Petra Marttila
RGRobert Gustafsson
Robert Gustafsson
THThomas Helleday
Thomas Helleday
The folate metabolism enzyme MTHFD2 (methylenetetrahydrofolate dehydrogenase/cyclohydrolase) is consistently overexpressed in cancer but its roles are not fully characterized, and current candidate inhibitors have limited potency for clinical development. In the present study, we demonstrate a role for MTHFD2 in DNA replication and genomic stability in cancer cells, and perform a drug screen to identify potent and selective nanomolar MTHFD2 inhibitors; protein cocrystal structures demonstrated binding to the active site of MTHFD2 and target engagement. MTHFD2 inhibitors reduced replication fork speed and induced replication stress followed by S-phase arrest and apoptosis of acute myeloid leukemia cells in vitro and in vivo, with a therapeutic window spanning four orders of magnitude compared with nontumorigenic cells. Mechanistically, MTHFD2 inhibitors prevented thymidine production leading to misincorporation of uracil into DNA and replication stress. Overall, these results demonstrate a functional link between MTHFD2-dependent cancer metabolism and replication stress that can be exploited therapeutically with this new class of inhibitors.

31 October 2016 in ACS Infectious Diseases
Verified
Journal Article
Open access
CWClaire E. Weston
Claire E. Weston
AKAndreas Krämer
Andreas Krämer
FCFelix Colin
Felix Colin
ÖYÖzkan Yildiz
Özkan Yildiz
MBMatthias Bauer
Matthias Bauer
MFMatthew J. Fuchter
Matthew J. Fuchter
Photopharmacological agents exhibit light-dependent biological activity and may have potential in the development of new antimicrobial agents/modalities. Amidohydrolase enzymes homologous to the well-known human histone deacetylases (HDACs) are present in bacteria, including resistant organisms responsible for a significant number of hospital-acquired infections and deaths. We report photopharmacological inhibitors of these enzymes, using two classes of photoswitches embedded in the inhibitor pharmacophore: azobenzenes and arylazopyrazoles. Although both classes of inhibitor show excellent inhibitory activity (nM IC50 values) of the target enzymes and promising differential activity of the switchable E- and Z-isomeric forms, the arylazopyrazoles exhibit better intrinsic photoswitch performance (more complete switching, longer thermal lifetime of the Z-isomer). We also report protein–ligand crystal structures of the E-isomers of both an azobenzene and an arylazopyrazole inhibitor, bound to bacterial histone deacetylase-like amidohydrolases (HDAHs). These structures not only uncover interactions important for inhibitor binding but also reveal conformational differences between the two photoswitch inhibitor classes. As such, our data may pave the way for the design of improved photopharmacological agents targeting the HDAC superfamily.

28 January 2020 in ACS Chemical Biology
Verified
Journal Article
Open access
MBMatthias Bauer
Matthias Bauer
AKAndreas Krämer
Andreas Krämer
GSGiovanni Settanni
Giovanni Settanni
RJRhiannon N. Jones
Rhiannon N. Jones
XNXiaomin Ni
Xiaomin Ni
AJAndreas C Joerger
Andreas C Joerger
We have previously shown that the thermolabile, cavity-creating p53 cancer mutant Y220C can be reactivated by small-molecule stabilizers. In our ongoing efforts to unearth druggable variants of the p53 mutome, we have now analyzed the effects of other cancer-associated mutations at codon 220 on the structure, stability and dynamics of the p53 DNA-binding domain (DBD). We found that the oncogenic Y220H, Y220N and Y220S mutations are also highly destabilizing, suggesting that they are largely unfolded under physiological conditions. A high-resolution crystal structure of the Y220S mutant DBD revealed a mutation-induced surface crevice similar to that of Y220C, whereas the corresponding pocket’s accessibility to small molecules was blocked in the structure of the Y220H mutant. Accordingly, a series of carbazole-based small molecules, designed for stabilizing the Y220C mutant, also bound to and stabilized the folded state of the Y220S mutant, albeit with varying affinities due to structural differences in the binding pocket of the two mutants. Some of the compounds also bound to and stabilized the Y220N mutant, but not the Y220H mutant. Our data validate the Y220S and Y220N mutant as druggable targets and provide a framework for the design of Y220S or Y220N-specific compounds as well as compounds with dual Y220C/Y220S specificity for use in personalized cancer therapy.

1 December 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AKAndreas Krämer
Andreas Krämer
CKChristian Georg Kurz
Christian Georg Kurz
Benedict-Tilman BergerBenedict-Tilman Berger
Benedict-Tilman Berger
ICIbrahim Ethem Celik
Ibrahim Ethem Celik
ATAmelie Tjaden
Amelie Tjaden
THThomas Hanke
Thomas Hanke